HF Advisory Group LLC Boosts Stock Holdings in Cencora, Inc. $COR

HF Advisory Group LLC increased its holdings in Cencora, Inc. (NYSE:COR) by 2,346.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,710 shares of the company’s stock after purchasing an additional 58,228 shares during the period. Cencora makes up about 0.8% of HF Advisory Group LLC’s investment portfolio, making the stock its 20th largest position. HF Advisory Group LLC’s holdings in Cencora were worth $20,505,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Marshall Wace LLP raised its stake in shares of Cencora by 518.9% during the third quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after acquiring an additional 1,672,762 shares in the last quarter. Mizuho Markets Americas LLC increased its holdings in shares of Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after acquiring an additional 1,511,906 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Cencora by 528.9% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Viking Global Investors LP raised its stake in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Cencora by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after buying an additional 916,506 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Morgan Stanley set a $380.00 price target on Cencora in a research report on Tuesday, March 17th. Wells Fargo & Company lifted their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Robert W. Baird set a $415.00 target price on shares of Cencora in a report on Tuesday, January 13th. Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Twelve equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $403.17.

Cencora Stock Performance

Shares of COR opened at $318.05 on Thursday. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The firm has a market cap of $61.87 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 1.46 and a beta of 0.72. Cencora, Inc. has a 12-month low of $267.40 and a 12-month high of $377.54. The company’s 50 day simple moving average is $349.74 and its 200-day simple moving average is $341.09.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period last year, the firm earned $3.73 EPS. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. As a group, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.